GlassScriptPhysician profile
Wasseem Skef
NPI 1558625699
$11,313.04
in general payments reported to CMS, 2019-2025
21 companies · $7,533 in 2025
The $7,533 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $342 · 2021: $443 · 2022: $211 · 2023: $1,283 · 2024: $562 · 2025: $7,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,720 · Food and Beverage: $2,152 · Travel and Lodging: $492 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,720.00 |
| Food and Beverage | $2,151.84 |
| Travel and Lodging | $492.48 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $6,755.00 | 2025 | Esophyx |
| Olympus Corporation of The Americas | $938.61 | 2019 | |
| Boston Scientific Corporation | $917.94 | 2020-2025 | Overstitch Endoscopic Suturing System, Apollo Esg Nxt System, Axios |
| Apollo Endosurgery US INC | $912.87 | 2021-2023 | Overstitch Endoscopic Suturing System |
| Conmed Corporation | $351.03 | 2023-2025 | Conmed Generators |
| Abbvie INC. | $279.64 | 2021-2024 | Linzess, Viberzi |
| Creo Medical INC. | $257.80 | 2023 | Speedboat |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Cook Medical LLC | $126.99 | 2025 | Hemospray |
| Endogastric Solutions, INC | $115.28 | 2021-2023 | Esophyx |
| E.R. Squibb & Sons, L.L.C. | $114.84 | 2021 | |
| Medtronic, INC. | $84.89 | 2024-2025 | Endoflip, Nexpowder |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.60 | 2022-2024 | Xifaxan |
| 3-D Matrix, INC. | $73.15 | 2024 | |
| Genzyme Corporation | $52.94 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $27.27 | 2025 | |
| Merck Sharp & Dohme LLC | $23.49 | 2023 | Dificid |
| Pfizer INC. | $15.40 | 2021 | |
| Laborie Medical Technologies Corp. | $15.06 | 2024 | Alphaone |
| Qol Medical, LLC | $14.99 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2024 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasseem Skef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.